2 months ago
VERV
AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 15%
#696 out of 4906 analysts
Average Return
+10.62%
Win Rate
39%35 out of 89
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-22 - 2021-03-09 | Strong Buy |
Scholar Rock Holding CorpSRRK | +284.02% | $8.45 | $32.45 | 2024-08-09 - 2025-06-13 | Buy |
C4 Therapeutics IncCCCC | +259.62% | $1.56 | $5.61 | 2023-11-03 - 2024-11-01 | Buy |
Scholar Rock Holding CorpSRRK | +253.34% | $9.43 | $33.32 | 2024-06-13 - 2025-06-12 | Buy |
Nuvalent IncNUVL | +222.66% | $13.59 | $43.85 | 2022-06-24 - 2023-06-23 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | 5 | Buy | $15.00 | +286.60% | Maintains | a month ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $24.00 | +289.61% | Maintains | 2 months ago |
Inventiva SaIVA | 3 | Strong Buy | $9.00 | +158.99% | Maintains | 2 months ago |
Arvinas IncARVN | 4 | Buy | $20.00 | +170.64% | Maintains | 3 months ago |
Protagonist Therapeutics IncPTGX | 2 | Buy | $72.00 | +27.73% | Reiterates | 3 months ago |
Biontech SeBNTX | 4 | Buy | $143.00 | +34.18% | Maintains | 3 months ago |
Q32 Bio IncQTTB | 3 | Hold | $3.00 | +79.64% | Downgrades | 4 months ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | +65.29% | Downgrades | 5 months ago |
Exelixis IncEXEL | 3 | Hold | $40.00 | -3.82% | Downgrades | 6 months ago |
Tourmaline Bio IncTRML | 1 | Buy | $50.00 | +154.07% | Initiates Coverage On | 6 months ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | +193.38% | Initiates Coverage On | 6 months ago |
Kymera Therapeutics IncKYMR | 1 | Hold | $55.00 | +17.12% | Initiates Coverage On | 6 months ago |
Jasper Therapeutics IncJSPR | 1 | Buy | $63.00 | +1,029.03% | Initiates Coverage On | 6 months ago |
Acrivon Therapeutics IncACRV | 7 | Buy | $27.00 | +2,150.00% | Maintains | 7 months ago |
Nuvalent IncNUVL | 6 | Buy | $134.00 | +71.27% | Maintains | 7 months ago |
Xencor IncXNCR | 5 | Buy | $34.00 | +269.97% | Reiterates | 7 months ago |
Genmab AGMAB | 3 | Buy | $48.00 | +110.34% | Reiterates | 7 months ago |
Novartis AgNVS | 3 | Hold | $120.00 | +0.46% | Maintains | 8 months ago |
Scholar Rock Holding CorpSRRK | 3 | Buy | $38.00 | +17.10% | Maintains | 8 months ago |
Y Mabs Therapeutics IncYMAB | 5 | Buy | $25.00 | +430.79% | Maintains | 10 months ago |
Macrogenics IncMGNX | 8 | Hold | $5.00 | +228.95% | Maintains | 10 months ago |
C4 Therapeutics IncCCCC | 3 | Buy | $20.00 | +1,090.48% | Reiterates | 10 months ago |
Merus NvMRUS | 5 | Buy | $91.00 | N/A | Maintains | a year ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | N/A | Maintains | a year ago |
Cytomx Therapeutics IncCTMX | 8 | Hold | $3.59 | N/A | Maintains | a year ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | N/A | Maintains | a year ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | 2 years ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | 2 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 3 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 4 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 4 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 4 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 5 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.